LEGIT – a crystal clear vision – is the fundamental attribute of LEGIT Medical Diagnostics as we look to bring in a fresh perspective and approach to diagnostics services in India. Taking off in the year 2006, LEGIT Medical Diagnostics has redefined Diagnostics Services, which until then occupied the lower rungs of the healthcare ladder. With improved facilities, state-of-the-art infrastructure and a whole new approach, LEGIT Medical Diagnostics has revolutionized this vital healthcare paradigm over the last decade.
The healthcare space in the 21st century is a highly dynamic and increasingly complex space. Both the complexity of diseases as well as treatment has increased and the need for accurate diagnosis has never been more pertinent. With the experience we have garnered – the diagnostic as well as therapeutic tools and expertise in the field of imaging and laboratory services – we are striving for more precise and timely results that are aided by seasoned healthcare professionals, state-of-the-art technology, and subspecialized radiologists and pathologists. With a decade long pedigree behind us, we still believe that our journey towards excellence has just begun. There is an endless scope for us to improve our protocols, expand our infrastructure and acquire new expertise. It is our objective to set, world-class standards in the field of diagnostics. In addition to strengthening our own laboratories and facilities, we also seek to evolve effective partnerships with other leading hospitals to standardize diagnostic services across a broader spectrum.
LEGIT has made rapid strides and we have expanded to over 45 centers in the last 10 years. Our spacious and modern facilities, qualified staff, and sophisticated medical systems from leading medical equipment manufacturers such as GE Medical systems, USA and SIEMENS AG, Germany, helps us stay ahead in this ever-changing field.
LEGIT is committed to working with all our stakeholders – patients, clinicians, and researchers – to better understand their needs, deliver the highest quality of service and consistently live up to their expectations. We firmly believe that creating value addition in healthcare is the best way of offering significant benefit to our stakeholders.
Consistent with our role as the industry leader and to focus our efforts on the opportunities ahead, our mission is:
The highest standards of quality remain our topmost priority. At LEGIT, we are guided by the Good Laboratory Practice standards and they are implemented throughout our designs and protocols. The result of this rigorous adherence to quality standards is that we produce reliable and accurate diagnostic results, every time.
To ensure that our practices are consistent with the best in the world, we frequently take part in external quality assurance programs as well. These include, CAP, Bio-Rad and other Proficiency Testing providers. LEGIT is one of the only three CAP (College of American Pathologists) accredited laboratories in South India. We are also accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL).
The safety of employees, patients and other stakeholders is paramount to our operations & existence. We take stringent measures to implement the highest protocols of workplace safety, which are regularly reviewed to check for deficiencies. Safety measures include
Lucid has consistently partnered with the leading equipment manufacturers in the field of healthcare investigations and imaging to deliver cutting edge services to patients and healthcare practitioners. Our partnerships include alliances with GE Medical Systems, USA and Siemens AG, Germany – which has enabled our rapid expansion and consistently high standards of accuracy.
We have partnered with Mapmygenome to offer personalized health solutions based on genetic tests. By combining genetic health profile and health history with genetic counseling, their solutions provide actionable steps for individuals and their physicians towards a healthier life. Mapmygenome also offers testing of rare disorders and cancers based on microarray and genome sequencing.